CARDIOSOLV™: A NEW PARADIGM FOR VT ABLATION
CardioSolv™ is an early stage company developing new strategies to improve the treatment of patients with Ventricular Tachycardia (VT), a life-threatening arrhythmia. Using proprietary software and algorithms, CardioSolv™ develops a patient-specific model that guides VT ablation therapy with the goal of improving patient outcomes while reducing procedure time and cost.
Company’s Keywords:
<5
<
<
<2012